Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by Generali Investments Towarzystwo Funduszy Inwestycyjnych

Generali Investments Towarzystwo Funduszy Inwestycyjnych boosted its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 33.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 24,000 shares of the medical research company's stock after purchasing an additional 6,000 shares during the quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych's holdings in Exact Sciences were worth $1,349,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. AMF Tjanstepension AB bought a new position in shares of Exact Sciences during the 3rd quarter worth approximately $724,000. International Assets Investment Management LLC purchased a new position in Exact Sciences in the third quarter worth $11,257,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Exact Sciences during the third quarter worth $49,000. Forsta AP Fonden purchased a new stake in shares of Exact Sciences during the 3rd quarter valued at $2,643,000. Finally, J.W. Cole Advisors Inc. acquired a new stake in shares of Exact Sciences in the 3rd quarter worth $512,000. 88.82% of the stock is owned by hedge funds and other institutional investors.

Exact Sciences Stock Performance

EXAS stock traded up $0.14 during trading on Monday, hitting $47.55. 2,151,937 shares of the company traded hands, compared to its average volume of 2,337,243. Exact Sciences Co. has a 1 year low of $40.62 and a 1 year high of $79.62. The company has a market cap of $8.83 billion, a PE ratio of -8.54 and a beta of 1.24. The stock's 50-day simple moving average is $53.93 and its 200 day simple moving average is $59.75. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93.

Remove Ads

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The firm had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million. On average, equities analysts expect that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Scotiabank upped their target price on Exact Sciences from $70.00 to $73.00 and gave the company a "sector outperform" rating in a research report on Monday, February 24th. Bank of America decreased their price objective on shares of Exact Sciences from $72.00 to $65.00 and set a "buy" rating for the company in a research report on Thursday, February 20th. TD Cowen boosted their target price on shares of Exact Sciences from $82.00 to $86.00 and gave the stock a "buy" rating in a research report on Tuesday, November 26th. Stifel Nicolaus decreased their price target on shares of Exact Sciences from $82.00 to $67.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. Finally, BTIG Research lifted their price objective on shares of Exact Sciences from $65.00 to $75.00 and gave the stock a "buy" rating in a research note on Tuesday, November 26th. One equities research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $71.94.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.